MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: BioPharmaceuticals_Inflammation, Allergy & Autoimmune
ARS Pharmaceuticals Inc. (NASDAQ: SPRY)*
Organization & Developments: ARS Pharmaceuticals
Parents
ARS Pharmaceuticals Inc. (NASDAQ: SPRY)*
Children
2023: ARS Pharmaceuticals: Surprise FDA Rejection Presents Cautious Opportunity_seekingalpha.com
2024: ARS Pharmaceuticals (SPRY): A Bull Case Theory
2024: ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United
2024: ARS Pharmaceuticals: Demand Curve Is Key Unknown
2024: ARS Pharmaceuticals' anaphylaxis nasal spray gains FDA approval
2024: In launching epinephrine nasal spray, ARS Pharma has a 'blue sky opportunity,' analyst says
2025: ARS Pharmaceuticals targets 80% commercial coverage for neffy in 2025 while expanding pediatric reach
2025: ARS Pharmaceuticals: Surging On Solid Earnings - But Real Challenges Await
2025: ARS Pharmaceuticals' Neffy Launch Could Be A Hit For Severe Allergic Reactions
2026: ARS Pharmaceuticals Stock: Climbing Neffy Sales Global Expansion Re-Rate (NASDAQ:SPRY)
Jumps
Finance & Acquisitions: ARS Pharmaceuticals
Key People: ARS Pharmaceuticals